Triazole-derivatives as factor Xa inhibitors

Details for Australian Patent Application No. 2004238498 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Bauer, Armin; Nazare, Marc; Wagner, Michael; Laux, Volker

Agent Watermark

Pub. Number AU-B-2004238498

PCT Pub. Number WO2004/101555

Priority 03011309.6 19.05.03 EP

Filing date 5 May 2004

Wipo publication date 25 November 2004

Acceptance publication date 22 July 2010

International Classifications

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2004/101555 Priority application(s): WO2004/101555

22 July 2010 Application Accepted

  Published as AU-B-2004238498

18 November 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004238499-Indazole-derivatives as factor Xa inhibitors

2004238497-Benzimidazole-derivatives as factor Xa inhibitors